MdxHealth Reports Preliminary Q4 and FY25 Revenues, Issues 2026 Guidance.
ByAinvest
Monday, Jan 12, 2026 8:17 am ET1min read
MDXH--
• MDxHealth reports preliminary Q4 and FY25 revenues of $30.5mln and $109mln. • Represents YoY growth of 23% and 21%, respectively. • Q4 saw 11,201 tissue-based units and 27,486 liquid-based units billed. • FY25 saw 49,180 tissue-based units and 104,066 liquid-based units billed. • Company expects 2026 revenue growth of 30-40%. • Amends earnout terms with Exact Sciences.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet